ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited as the Company’s Nominated Advisor, with immediate effect.
Commenting on the appointment, ImmuPharma plc Chairman, Tim McCarthy, said:
“I am delighted to announce the appointment of SPARK as the Company’s NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital.”
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of the story as its scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.
